TSD is caused by inactivating mutations in the gene for lysosomal GM2 ganglioside-degrading enzyme beta-hexosaminidase (HEXA) and represents an attractive target for enzyme replacement therapy. The gene discussed is HEXA; the disease is Tay-Sachs disease.